![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 25, 2023
This phase 3 study of oligometastatic head and neck cancer is exploring whether it is more effective to add radiation therapy to standard immunotherapy in patients with stable disease after initial chemotherapy plus immunotherapy
August 25, 2023
The ECOG-ACRIN Sarcoma Working Group has launched its first trial, an international collaboration to evaluate chemotherapy prior to surgery in patients with retroperitoneal leiomyosarcoma or dedifferentiated liposarcoma
June 30, 2023
Reflections on the spring conference season, including highlights from the recent Group Meeting; updates on the ComboMATCH precision medicine initiative
June 30, 2023
Earlier this year, Puerto Rico lost its preeminent champion for cancer research
June 30, 2023
This phase 2 trial is testing how well FDG-PET/CT imaging can predict response to standard-of-care neoadjuvant therapy in patients with HER2-positive breast cancer
June 30, 2023
This phase 2 trial is evaluating the activity of nilotinib-paclitaxel in patients with solid tumors and exploring predictive biomarkers of response and resistance
June 30, 2023
At a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
June 30, 2023
This phase 3 study aims to determine the optimal sequencing of surgery, chemotherapy, and chemoradiotherapy for patients with cancer of the penis
April 19, 2023
The ComboMATCH registration trial opens; NCI creates Clinical Trials Innovation unit, unveils revised National Cancer Plan
February 10, 2023
Plans for the year ahead; a focus on data; the future of cancer screening studies
December 20, 2022
Reflections on NCI-MATCH and its successor trials; research results in leukemia and breast cancer; and grant renewal preparations
December 20, 2022
This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population